TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System ...

TransMedics Group (NASDAQ: TMDX) has emerged as a medical devices industry leader, capturing strong growth and climbing profitability from its organ transplant delivery system. Since the company's ...

Stock performance context for TransMedics Group investors TransMedics Group (TMDX) has drawn attention after a period of weak share performance, with the stock down about 7% over the past day and ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

TransMedics' stock tanked after the company reported third-quarter results. Third-quarter sales rose 64% year over year, but fell slightly compared to the previous quarter. The pullback coincided with ...

TransMedics (TMDX) is still rated a Strong Buy after a 50% drop and Q1 miss—see growth drivers, Europe rollout, guidance, and ...

Here's our initial take on TransMedics' (NASDAQ: TMDX) second-quarter financial report. TransMedics reported second-quarter financial results that were considerably better than most investors had ...

To find out if TransMedics is a good growth stock to buy now, we'll need to weigh the reasons it soared against some of the challenges it faces. In a nutshell, TransMedics stock began 2025 in a ...

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

TransMedics reported second-quarter financial results that were considerably better than most investors had anticipated. On the sales front, gains of 38% to $157 million were healthily higher than ...

From the beginning of 2024 through Aug. 23, shares of TransMedics (NASDAQ: TMDX) stock soared by 123% -- but the good times didn't last. A third-quarter earnings miss sent shares of the ...